We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+16.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$593M
AUM Growth
+$248M
Cap. Flow
+$187M
Cap. Flow %
31.46%
Top 10 Hldgs %
30.55%
Holding
100
New
16
Increased
48
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13.1M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$12.8M
3
NKTR icon
Nektar Therapeutics
NKTR
+$10.4M
4
UHS icon
Universal Health Services
UHS
+$9.62M
5
AMGN icon
Amgen
AMGN
+$9.42M

Top Sells

Rank Stock Value
1
UTI icon
Universal Technical Institute
UTI
+$6.79M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$5.83M
3
GILD icon
Gilead Sciences
GILD
+$4.79M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.37M
5
CELG
Celgene Corp
CELG
+$3.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.68%
2 Financials 0.74%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLB icon
1
PUT
State Street Materials Select Sector SPDR ETF
XLB
$8.5B
$31.9M 5.38%
+880,000
New +$21.8M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$19.9M 3.36%
114,978
+70,978
+161% +$12.8M
CELG
3
DELISTED
Celgene Corp
CELG
$17.4M 2.94%
151,000
-31,000
-17% -$3.7M
MRK icon
4
Merck
MRK
$322B
$17.2M 2.91%
314,400
+230,560
+275% +$13.1M
BIIB icon
5
Biogen
BIIB
$30B
$17.2M 2.9%
40,700
+19,200
+89% +$7.57M
AMGN icon
6
Amgen
AMGN
$208B
$15.8M 2.67%
99,000
+59,832
+153% +$9.42M
ALKS icon
7
Alkermes
ALKS
$8.22B
$15.7M 2.65%
258,000
+115,000
+80% +$7.86M
GILD icon
8
Gilead Sciences
GILD
$162B
$15.6M 2.63%
159,000
-47,138
-23% -$4.79M
UNH icon
9
UnitedHealth
UNH
$376B
$15.4M 2.59%
130,000
+63,000
+94% +$7M
CVS icon
10
CVS Health
CVS
$133B
$15M 2.52%
145,000
+48,000
+49% +$4.86M
AGN
11
DELISTED
Allergan plc
AGN
$13.5M 2.27%
45,300
+18,300
+68% +$5.22M
ABBV icon
12
AbbVie
ABBV
$443B
$12.9M 2.17%
220,000
+80,000
+57% +$4.83M
CAH icon
13
Cardinal Health
CAH
$53.9B
$12.8M 2.15%
141,400
+71,400
+102% +$6.15M
ESPR
14
DELISTED
Esperion Therapeutics
ESPR
$11.8M 1.98%
126,926
-23,074
-15% -$1.49M
RAD
15
DELISTED
Rite Aid Corporation
RAD
$11.1M 1.87%
63,823
+24,573
+63% +$3.83M
INCY icon
16
Incyte
INCY
$24.2B
$11M 1.85%
120,000
+76,000
+173% +$6.28M
NKTR icon
17
Nektar Therapeutics
NKTR
$2.39B
$11M 1.85%
66,440
+50,573
+319% +$10.4M
UHS icon
18
Universal Health Services
UHS
$10.2B
$10.2M 1.73%
+87,000
New +$9.62M
REGN icon
19
Regeneron Pharmaceuticals
REGN
$78.5B
$9.93M 1.67%
22,000
-500
-2% -$212K
JAZZ icon
20
Jazz Pharmaceuticals
JAZZ
$15.9B
$9.5M 1.6%
55,000
+37,600
+216% +$6.45M
LLY icon
21
Eli Lilly
LLY
$1.02T
$9.37M 1.58%
129,000
+63,000
+95% +$4.49M
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.6B
$9.35M 1.58%
75,000
+14,000
+23% +$1.48M
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$8.91M 1.5%
138,000
-3,400
-2% -$195K
ELV icon
24
Elevance Health
ELV
$81.5B
$8.8M 1.48%
57,000
+16,000
+39% +$2.28M
MCK icon
25
McKesson
MCK
$100B
$8.6M 1.45%
38,000
+22,000
+138% +$4.88M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rhenman & Partners Asset Management held 100 positions worth $593M, up 72% from $345M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $187M of net new capital in Q1 2015, opening 16 new positions and adding to 48 existing holdings. Its largest new stake was Universal Health Services: 87,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $4.79M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2015 buy was Universal Health Services: 87,000 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Merck in Q1 2015, an estimated $13.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $4.79M.
  • Rhenman & Partners Asset Management fully exited Universal Technical Institute in Q1 2015, selling an estimated $6.79M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $593M portfolio in Q1 2015.
  • Rhenman & Partners Asset Management opened 16 new positions and closed 11 in Q1 2015.
  • Rhenman & Partners Asset Management's portfolio value rose 72% quarter-over-quarter to $593M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2015, filed 13 May 2015.